Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up

Leukemia Research

Volumn 36, Issue 11, 2012, Pages 1393-1397

  Matsuda, Kazuyuki ^a   Ishida, Fumihiro ^b   Ito, Toshiro ^b   Nakazawa, Hideyuki ^b   Miura, Shuhei ^a   Taira, Chiaki ^a   Sueki, Akane ^a   Kobayashi, Yukihiro ^a   Honda, Takayuki ^a  

^a SHINSHU UNIVERSITY HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Allele specific quantitative PCR; Hematopoietic stem cell transplantation; Minimal residual disease; Single nucleotide mutations; Spliceosome related mutation

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA EXTRACTION; EXON; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SF3B1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICEOSOME; TUMOR GENE; U2AF1 GENE;

BIOLOGICAL MARKERS; DNA MUTATIONAL ANALYSIS; FOLLOW-UP STUDIES; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; SPLICEOSOMES;

EID: 84866341038     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.07.019     Document Type: Article

References (39)

1. Nikoloski G., van der Reijden B.A., Jansen J.H. Mutations in epigenetic regulators in myelodysplastic syndromes. Int J Hematol 2012, 95:8-16.
2. Visconte V., Makishima H., Jankowska A., Szpurka H., Traina F., Jerez A., et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012, 26:542-545.
3. Yoshida K., Sanada M., Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
4. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365:1384-1395.
5. Malcovati L., Papaemmanuil E., Bowen D.T., Boultwood J., Della Porta M.G., Pascutto C., et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011, 118:6239-6246.
6. Damm F., Thol F., Kosmider O., Kade S., Löffeld P., Dreyfus F., et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2012, 26:1137-1140.
7. Lasho T.L., Finke C.M., Hanson C.A., Jimma T., Knudson R.A., Ketterling R.P., et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 2012, 26:1135-1137.
8. Patnaik M.M., Lasho T.L., Hodnefield J.M., Knudson R.A., Ketterling R.P., Garcia-Manero G., et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012, 119:569-572.
9. Graubert T.A., Shen D., Ding L., Okeyo-Owuor T., Lunn C.L., Shao J., et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2011, 44:53-57.
10. Makishima H., Visconte V., Sakaguchi H., Jankowska A.M., Abu Kar S., Jerez A., et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012, 119:3203-3210.
11. Damm F., Kosmider O., Gelsi-Boyer V., Renneville A., Carbuccia N., Hidalgo-Curtis C., et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012, 119:3211-3218.
12. Matsuda K., Sakashita K., Taira C., Tanaka-Yanagisawa M., Yanagisawa R., Shiohara M., et al. Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia. Br J Haematol 2010, 148:593-599.
13. Taira C., Matsuda K., Kamijyo Y., Sakashita K., Ishida F., Kumagai T., et al. Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course. Clin Chim Acta 2011, 412:53-58.
14. Matsuda K., Sugano M., Honda T. PCR for monitoring of minimal residual disease in hematologic malignancy. Clin Chim Acta 2012, 413:74-80.
15. Taira C., Matsuda K., Saito S., Sakashita K., Sugano M., Okumura N., et al. Application of allele-specific quantitative PCR using genomic DNA to monitor minimal residual disease based on mutant gene levels following allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies: comparison of mutant levels with autologous DNA percentage by short tandem repeat-PCR. Clin Chim Acta 2012, 413:516-519.
16. Matsuda K., Yoshida N., Miura S., Nakazawa Y., Sakashita K., Hyakuna N., et al. Long-term haematological improvement after non-intensive or no chemotherapy in juvenile myelomonocytic leukaemia and poor correlation with adult myelodysplasia spliceosome-related mutations. Br J Haematol 2012, 157:647-650.
17. Nussenzveig R.H., Swierczek S.I., Jelinek J., Gaikwad A., Liu E., Verstovsek S., et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007, 35:32-38.
18. Mandigers C.M., Meijerink J.P., Mensink E.J., Tönnissen E.L., Hebeda K.M., Bogman M.J., et al. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 2001, 98:940-944.
19. Gelsi-Boyer V., Trouplin V., Adélaïde J., Bonansea J., Cervera N., Carbuccia N., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145:788-800.
20. Thol F., Damm F., Lüdeking A., Winschel C., Wagner K., Morgan M., et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011, 29:2889-2896.
21. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Massé A., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
22. Abdel-Wahab O., Kilpivaara O., Patel J., Busque L., Levine R.L. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia 2010, 24:1656-1657.
23. Meloni G., Mancini M., Gianfelici V., Martelli M.P., Foa R., Falini B. Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. Haematologica 2009, 94:298-300.
24. Palmisano M., Grafone T., Ottaviani E., Testoni N., Baccarani M., Martinelli G. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. Haematologica 2007, 92:1268-1269.
25. Kristensen T., Møller M.B., Friis L., Bergmann O.J., Preiss B. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. Eur J Haematol 2011, 87:40040-40048.
26. Cloos J., Goemans B.F., Hess C.J., van Oostveen J.W., Waisfisz Q., Corthals S., et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006, 20:1217-1220.
27. Chou W.C., Tang J.L., Lin L.I., Yao M., Tsay W., Chen C.Y., et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006, 66:3310-3316.
28. Hou H.A., Huang T.C., Lin L.I., Liu C.Y., Chen C.Y., Chou W.C., et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010, 115:5222-5231.
29. Hou H.A., Kuo Y.Y., Liu C.Y., Chou W.C., Lee M.C., Chen C.Y., et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012, 119:559-568.
30. Chou W.C., Lei W.C., Ko B.S., Hou H.A., Chen C.Y., Tang J.L., et al. The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011, 25:246-253.
31. Chou W.C., Peng K.Y., Lei W.C., Ko B.S., Tsay W., Kuo C.H., et al. Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. Leukemia 2012, 26:527-529.
32. Kindwall-Keller T., Isola L.M. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant 2009, 43:597-609.
33. Platzbecker U., Wermke M., Radke J., Oelschlaegel U., Seltmann F., Kiani A., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012, 26:381-389.
34. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
35. Itzykson R., Fenaux P. Optimizing hypomethylating agents in myelodysplastic syndromes. Curr Opin Hematol 2012, 19:65-70.
36. Traina F., Jankowska A.M., Visconte V., Sugimoto Y., Szpurka H., Makishima H., et al. Impact of molecular mutations on treatment response to hypomethylating agents in MDS. Blood 2011, 118:461. abstract.
37. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
38. Lange T., Hubmann M., Burkhardt R., Franke G.N., Cross M., Scholz M., et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 2011, 25:498-505.
39. Tobiasson M., Olsson R., Hellström-Lindberg E., Mattsson J. Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant 2011, 46:719-726.